Eli Lilly And CompanyCatalio Capital ManagementDeep Track CapitalPerceptive AdvisorsRA Capital ManagementInsight PartnersNvidiaCooleyGaingelsBVF Partners L.P.
Description
Superluminal Medicines, a biotechnology company, has closed an oversubscribed $60 million Series B financing. The proceeds will support the initiation of a Phase 1 clinical trial for rare genetic forms of obesity by the end of 2026. The financing was led by BVF Partners, L.P., with participation from Deep Track Capital, Perceptive Advisors, and existing investors. This marks a significant milestone as the company transitions to a clinical-stage biotechnology company.
Who to call at Superluminal Medicines, and when
A new round usually means Superluminal Medicines is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Superluminal Medicines raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Superluminal Medicines, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Superluminal Medicines
Location
Boston, Massachusetts, United States
About
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.
Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Superluminal Medicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BostonBiotechnologyHealth Care